1421372-94-2 Usage
Description
N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is a complex organic compound characterized by its unique molecular structure. It is a derivative of pyrimidinamine, featuring a fluoro, methoxy, and nitro group on the phenyl ring, and a methylindole moiety attached to the pyrimidine core. N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is known for its potential applications in the pharmaceutical and chemical industries due to its specific molecular interactions and properties.
Uses
Used in Pharmaceutical Industry:
N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is used as a reagent for the synthesis of dihydropyrroloquinoline derivatives. These derivatives possess significant anticancer activity, particularly as modulators of the epidermal growth factor receptor (EGFR). The compound is specifically designed to inhibit the L858R/T790M mutation, which is a common resistance mutation in non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors.
The application reason for using N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine in this context is its ability to form dihydropyrroloquinoline derivatives with potent anticancer properties. These derivatives can effectively target and inhibit the EGFR L858R/T790M mutation, providing a potential therapeutic strategy for overcoming resistance to EGFR-targeted therapies in lung cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1421372-94-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,1,3,7 and 2 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1421372-94:
(9*1)+(8*4)+(7*2)+(6*1)+(5*3)+(4*7)+(3*2)+(2*9)+(1*4)=132
132 % 10 = 2
So 1421372-94-2 is a valid CAS Registry Number.
1421372-94-2Relevant articles and documents
Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation
Yang, Tingting,Zhang, Wenjuan,Cao, Shengjie,Sun, Shiyang,Cai, Xu,Xu, Lei,Li, Pengyun,Zheng, Zhibing,Li, Song
, (2021/11/22)
Epidermal growth factor receptor (EGFR) is the most attractive target for drug research in non-small cell lung cancer (NSCLC). There have been three generation drugs developed to treat of NSCLC. The third-generation EGFR tyrosine kinase inhibitors (TKIs)
Refinement of covalent EGFR inhibitor AZD9291 to eliminate off-target activity
Bouffard, Elise,Cravatt, Benjamin,Dix, Melissa M.,Wong, Chi-Huey,Zaro, Balyn W.
supporting information, (2021/05/29)
Non-small-cell lung cancer (NSCLC) is a major disease that accounts for 85% of all lung cancer cases which claimed around 1.8 billion lives worldwide in 2020. Tyrosine kinase inhibitors (TKIs) that target EGFR have been used for the treatment of NSCLC, but often develop drug resistance, and the covalent inhibitor AZD9291 has been developed to tackle the problem of drug resistance mediated by the T790M EGFR mutation; however, there is a side effect of hyperglycemia that may be due to off-target activity. This study examines analogs of AZD9291 by chemical proteomics, identifying analogs that maintain T790M-EGFR engagement while showing reduced cross-reactivity with off-targets.
P-phenylenediamine LSD1 inhibitor and preparation method thereof
-
, (2021/09/08)
Disclosed are a p-phenylenediamine derivative as represented by general formula I, a pharmaceutically acceptable salt, and a stereoisomer thereof. The p-phenylenediamine derivative as represented by general formula I, the pharmaceutically acceptable salt thereof and the stereoisomer thereof can be used alone or in combination as lysine-specific demethylase-1 (LSD1) inhibitors.
